Skip to main content
Unichem Laboratories Ltd. logo

Unichem Laboratories Ltd. — Investor Relations & Filings

Ticker · UNICHEMLAB ISIN · INE351A01035 LEI · 3358008AHXLO9H4C2Q20 BSE.NS Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2026-05-22 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS UNICHEMLAB

About Unichem Laboratories Ltd.

https://www.unichemlabs.com/

Unichem Laboratories Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The company provides solutions across various therapeutic areas, including cardiology, gastroenterology, anti-infectives, diabetology, orthopedics, and neurology. It maintains a significant international footprint, exporting products to regulated markets such as the United States and Europe. The manufacturing infrastructure is built to comply with global standards, featuring approvals from international regulatory agencies. Through its dedicated research and development initiatives, the organization develops a robust pipeline of generic products and complex formulations aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Audited Financial Results for the year ended 31st March 2026
Interim / Quarterly Report Classification · 78% confidence The document is a board meeting outcome notice under SEBI LODR, but it encloses the full unaudited quarterly financial results for Q4 ending 31 March 2026 and the audited consolidated and standalone financial statements for the year ended 31 March 2026, including P&L, balance sheet, cash flows and notes. This is not merely an earnings press release (it contains full financial schedules and auditor’s report), nor is it a proxy or management change solely. It is a substantive quarterly/interim financial report, so it best fits the Interim/Quarterly Report category. FY 2026
2026-05-22 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 84% confidence The document is a disclosure under SEBI Listing Regulations dated 22 May 2026 titled “Outcome of Board Meeting.” It notifies the stock exchanges of several board decisions (redesignation and re-appointments) but, most importantly, encloses the actual unaudited quarterly results for Q4 (31 Mar 2026) and audited full-year financial statements (P&L, balance sheet, cash flows, and notes). Since it includes substantive financial statements for a period shorter than a full fiscal year (quarterly) and detailed numbers (not just highlights), it fits the definition of an Interim / Quarterly Report rather than a simple earnings release or an annual report. Therefore, it should be classified as IR. FY 2026
2026-05-22 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 86% confidence The document is headed “Outcome of Board Meeting” under SEBI Listing Regulations and directly encloses the full unaudited quarterly results for Q4 (31 Mar 2026) along with audited full‐year statements, balance sheet, cash flows and audit report. It is not a short announcement linking to a separate report (so not RPA/RNS), nor a high‐level earnings summary (ER), nor a full annual report with narrative and governance sections (10-K). It contains substantive interim period (quarterly) financial statements and therefore fits the definition of an Interim/Quarterly Report. FY 2026
2026-05-22 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2026-04-20 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2026-04-13 English
Updates
Regulatory Filings
2026-04-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.